CAPTRUST Financial Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-11,428
| Closed | -$635K | – | 2380 |
|
|
2024
Q3 | $635K | Buy |
11,428
+6,445
| +129% | +$358K | ﹤0.01% | 1453 |
|
|
2024
Q2 | $205K | Buy |
+4,983
| New | +$205K | ﹤0.01% | 2028 |
|
|
2024
Q1 | – | Sell |
-21,560
| Closed | -$1.03M | – | 2545 |
|
|
2023
Q4 | $1.03M | Sell |
21,560
-1,748
| -7% | -$83.6K | ﹤0.01% | 1248 |
|
|
2023
Q3 | $831K | Sell |
23,308
-1,532
| -6% | -$54.6K | ﹤0.01% | 1311 |
|
|
2023
Q2 | $1.15M | Buy |
+24,840
| New | +$1.15M | ﹤0.01% | 1125 |
|
|
2022
Q3 | – | Sell |
-404
| Closed | -$24K | – | 3589 |
|
|
2022
Q2 | $24K | Buy |
404
+145
| +56% | +$8.61K | ﹤0.01% | 3272 |
|
|
2022
Q1 | $19K | Buy |
259
+11
| +4% | +$807 | ﹤0.01% | 3423 |
|
|
2021
Q4 | $21K | Buy |
248
+114
| +85% | +$9.65K | ﹤0.01% | 3258 |
|
|
2021
Q3 | $12K | Sell |
134
-6
| -4% | -$537 | ﹤0.01% | 3505 |
|
|
2021
Q2 | $13K | Sell |
140
-534
| -79% | -$49.6K | ﹤0.01% | 3392 |
|
|
2021
Q1 | $77K | Buy |
674
+133
| +25% | +$15.2K | ﹤0.01% | 2139 |
|
|
2020
Q4 | $75K | Buy |
+541
| New | +$75K | ﹤0.01% | 1651 |
|